AstraZeneca-Daiichi’s breast cancer drug improves survival in study

2022.08.15 09:50

FILE PHOTO: AstraZeneca’s cancer medicine Enhertu, a drug developed jointly with Japan’s Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. AstraZeneca/Handout via REUTERS

(Reuters) – AstraZeneca (NASDAQ:AZN) said on Monday its cancer treatment, Enhertu, developed with Japan’s Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients.

Enhertu met the main goal of a late-stage study testing the drug against a treatment pre-determined by physicians in people with HER2-positive metastatic breast cancer. The HER2 protein contributes to the growth and spread of breast cancer.

Source